期刊文献+

脐血造血细胞体外集落培养最佳收获时机的探讨 被引量:2

Observation on the optimum time for harvesting hematopoietic cells from cord blood after culture in vitro.
暂未订购
导出
摘要 目的探讨脐血(CB)多系造血集落培养在不同培养条件下脐血造血细胞体外扩增的最佳收获时机。方法将从新鲜CB标本中分离出的单个核细胞(MNC)分别接种于已建立的无血清培养基,该培养基分别含单用人骨髓基质细胞、单用细胞因子及细胞因子联合入骨髓基质细胞(HBMSC)支持培养体系。在0、6、10及14d各时间点分别取细胞进行巨细胞集落形成单位(CFU-MK)、红系爆式集落形成单位(BFU-E)及粒单细胞集落形成单位(CFU-GM)培养。结果在体外培养过程中,第10d时各组CFU-MK、BFU-E及CFU-GM数均高于组内其它时间点(P<0.05);在含HBMSC支持培养的组集落生成数优于其它组(P<0.05)。结论脐血MNC体外培养过程中,第10d可能是收获的最佳时机。FIBMSC能更好地维持造血干/祖细胞的活性,使其集落形成能数得到有效扩增。 Objective To explore the optimal time for harvesting cord blood hematopoietic ceils cultured in vitro by colony multiplication. Methods Mononuclear ceils separated from cord blood were cultured in a serum - free system supplemented with cytokines or human bone marrow stromal ceils of combination of tbem. CFU - MK, BFU- E and CFU- Gm were assessed by semisolid culture assay on d0, d6, d10 and d14 for determination of progenitor umber. Results The quantity of CFU - MK, BFU - E and CFU - Gm on d10 after culture were significantly higher than that of other culture time ( P 〈 0. 05 ). The number of colony forming units were higher in the groups supported with human bone marrow stromal ceils ( P 〈 0. 05). Conclusion The optimal time for harvesting the mononuclear ceils is on the tenth day after in vitro culture of cord blood hematopoietic ceils. Bone marrow stromal ceils is capable of maintaining the activity of hematopoietic ceils cultured in vitro.
出处 《中国热带医学》 CAS 2006年第9期1557-1558,共2页 China Tropical Medicine
基金 国家自然科学基金项目(30471644) 广州市科技攻关重点项目(2002Z2-E0241).
关键词 基质细胞 脐血 集落 Stromal ceil Cord blood Colony
  • 相关文献

参考文献2

二级参考文献23

  • 1Tao H, Gaudry L, Rice A, et al. Cord blood is better than bone marrow for generating megakaryocytic progenitor cells. Exp Hematol,1999;27:293-301
  • 2Schatmer M, Lefebvre P, Mingolelli SS, et al. Thrombopoietinstimulated ex vivo expansion of human bone marrow megakaryocytes. Stem Cells,1996;14:207-214
  • 3van den Oudenrijn S, von dcm Borne AE, de Haas M. Influence of medium components on ex vivo megakaryocyte expansion. J Hematother Stem Cell Res,2001;10:193-200
  • 4Lefebvre P, Winter JN, Kahn LE, et al. Megakaryocyte ex vivo expansion potential of three hematopoietic sources in serum and serum-free medium. J Hematother,1999;8:199-208
  • 5Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood,2002;
  • 6Watts MJ, Somervaille TC, Ings SJ, et al. Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices. BrJ Haematol,2002;118:117-123
  • 7Lazzari L, Henschler R, Leechi L, et al. Interleukin-6 and interleukin-11 act synergistically with thrombopoietin and stem cell factor to modulate ex vivo expansion of human CD41+ and CD61+megakaryocytic cells. Haematologica,2000;85:25-30
  • 8van den Oudenrijn S, von dem Bome AE, de Haas M. Differences in megakaryocyte expansion potential between CD34 + stem cells derived from cord blood, peripheral blood, and bone marrow from adults and children. Exp Hematol,2000;28:1054-1061
  • 9Mwarmtemi HH, Higuchi T, Sawai N, et al. Quantitative and qualitative differences in thrombopoietin-dependent hematopoietic progenitor development between cord blood and bone marrow. Transplantation,2000;69:1645-1654
  • 10Bruno S, Gunetti M, Gammaitoni L, et al. In vitro and in vivo megakaryocyte differentiation of fresh and ex-vivo expanded cord blood cells: rapid and transient megakaryocyte reconstitution.Haematologica,2003;88:379-387

共引文献17

同被引文献13

  • 1王彩霞,毛平,林秀梅,杜庆华.人骨髓基质细胞支持脐血单个核细胞体外扩增[J].中华器官移植杂志,2005,26(10):616-618. 被引量:6
  • 2毛平,彭盘俐,许力.人脐血单个核细胞体外扩增后植入NOD/SCID小鼠重建多系造血[J].中华器官移植杂志,2006,27(4):231-234. 被引量:13
  • 3孙玉兰,胡义德.线粒体DNA与肿瘤关系的研究进展[J].中华肿瘤防治杂志,2006,13(12):951-955. 被引量:8
  • 4Wagner JE, Barker JN, Defor TE, et al.Transplantation of unrelated donor umbilical cord blood in 102 patient with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood,2002; 100(5) : 1611 -1618.
  • 5Conrad PD, Emerson SG. Ex vivo expansion of hematopoietic cells from umbilical cord blood for clinical transplant. J Leuk Biol, 1998; 64(2) : 147 -155.
  • 6Locatelli F, Rocha V, Chastang C, et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia: Eurocord-Cord Blood Transplant Group. Blood, 1999; 93(11) : 3662 -3671.
  • 7Brtmstein CG, Wagner JE. Umbilical cord blood transplantation and banking. Annu Rev Med, 2006; 57:403 -417.
  • 8Visioli F, Grande S, Bogani P, et al. The role of antioxidants in the mediterranean diets : focus on cancer. Eur J Cancer Prey, 2004 ; 13(4) : 337 -343.
  • 9Singh NP, McCoy MT, Tice RR, et al. Asimple technique for quantitation of low levels of DNA dmage in individual cells, Exp Cell Res, 1988 ; 175 ( 1 ) : 184 - 191.
  • 10Buschfort-Papewalis C, Moritz T, Liedert B, et al. Down-regulation of DNA repair in human CD34^+ progenitor cells corresponds to increased drug sensitivity and apoptotic response. Blood, 2002; 100(3) : 845 -853.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部